Agenus (AGEN) Presents New Phase 1b Clinical Data on BOT/BAL Combination for MSS mCRC

Agenus Inc. (NASDAQ:AGEN) is one of the most undervalued penny stocks to buy right now. On February 19, Agenus presented new translational and clinical biomarker data from its Phase 1b C-800-01 trial, focusing on the combination of botensilimab/BOT and balstilimab/BAL. The study highlighted the therapy’s effectiveness in immunologically cold tumors, such as microsatellite-stable metastatic colorectal cancer/MSS mCRC, which typically resist standard immunotherapies.

In a group of 341 evaluable patients, the combination achieved an objective response rate of 17% and a median overall survival of 17.2 months, with a 24-month survival rate of 38%. The research introduced a biologically grounded approach to patient stratification by balancing systemic inflammation markers in the blood against immune activity within the tumor microenvironment.

NASDAQ:AGEN

Photo by National Cancer Institute on Unsplash

Findings indicated that while high systemic inflammation correlates with poorer outcomes, BOT+BAL can provide clinical benefits even in patients with low levels of immune infiltration that would normally disqualify them from conventional checkpoint inhibitor treatment. This suggests that the Fc-enhanced mechanism of botensilimab lowers the necessary threshold of baseline immunity required for a successful clinical response. Agenus Inc. continues to develop its pipeline of immunological agents, using these findings to expand the population of patients who can benefit from next-gen cancer immunotherapies.

Agenus Inc. is a clinical-stage biotechnology company that discovers and develops therapies to activate the body’s immune system against cancer and infections internationally.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street.